查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1638850

乳癌液体活检市场机会、成长驱动因素、产业趋势分析与预测 2024 - 2032

Breast Cancer Liquid Biopsy Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球乳癌液体活检市场达到 3.059 亿美元，预计 2024 年至 2032 年复合年增长率将达到 22.6%。包括新一代定序 (NGS) 在内的液体活检创新技术因其高精度和微创方法而受到关注，使早期检测和个人化治疗变得更加容易和有效。

人们对遗传倾向和遗传性癌症风险的认识不断提高，进一步推动了对这些技术的需求。液体活检技术透过提供详细的分子见解来帮助指导靶向癌症治疗，从而支持更精确、个人化的治疗计划。

按生物标记类型细分，cfDNA 细分市场预计到2023 年将保持22.5% 的强劲复合年增长率。和疾病进展。与传统的组织活检相比，cfDNA 提供了全面的基因组图谱，并且可以检测与抗药性相关的新兴突变，从而提高了其在癌症诊断中的实用性。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 3.059 亿美元
预测值 19亿美元
复合年增长率 22.6%

在产品和服务方面，市场分为试剂盒和试剂和服务产品，到2023年，试剂盒和试剂将占据67.1%的份额。乳癌盛行率的上升增加了对这些试剂盒的需求，推动了早期癌症检测领域的持续研究和新产品的推出。

2023年北美乳癌液体切片市场估值为1.333亿美元。该国先进的医疗基础设施和大量的研发投资促进了液体活检技术的实施，作为传统方法的非侵入性替代品。美国乳癌发生率不断上升，进一步刺激了对这些创新诊断工具的需求，凸显了该地区在该市场的领导地位。

因此，在技术创新、早期癌症检测工作以及对患者特异性治疗策略的日益重视的推动下，全球乳癌液体活检市场预计将显着增长。这种扩张反映了人们日益转向微创诊断技术，以提高准确性并改善患者治疗效果。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 乳癌盛行率上升
      • 液体切片技术的技术进步
      • 提高早期诊断和治疗意识
      • 扩大研发
    • 产业陷阱与挑战
      • 切片设备成本高
      • 严格的监管要求
  • 成长潜力分析
  • 流行病学情景
  • 监管环境
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按生物标誌物，2021 - 2032 年

  • 主要趋势
  • 循环肿瘤细胞 (CTC)
  • 游离 DNA (cfDNA)
  • 外泌体
  • 其他生物标誌物

第 6 章：市场估计与预测：按产品和服务分类，2021 - 2032 年

  • 主要趋势
  • 试剂盒和试剂
  • 服务

第 7 章：市场估计与预测：按样本类型，2021 - 2032

  • 主要趋势
  • 血
  • 尿
  • 其他样品类型

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院
  • 癌症研究中心
  • 诊断中心
  • 学术及研究机构

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Datar Cancer Genetics
  • Epic Sciences
  • F. Hoffmann-La Roche
  • Genes2me
  • Illumina
  • Menarini Silicon Biosystems
  • Myriad Genetics
  • OncoDNA
  • QIAGEN
  • Sysmex Corporation
  • System Biosciences
  • Thermo Fisher Scientific
  • Twist Bioscience
简介目录
Product Code: 12188

The Global Breast Cancer Liquid Biopsy Market reached USD 305.9 million in 2023 and is projected to expand at a robust CAGR of 22.6% from 2024 to 2032. Rising breast cancer incidence and advancements in diagnostic technologies are driving this growth. Liquid biopsy innovations, including next-generation sequencing (NGS), are gaining traction due to their high accuracy and minimally invasive methods, making early detection and personalized treatment more accessible and effective.

Increased awareness around genetic predispositions and inherited cancer risks is further fueling the demand for these technologies. Liquid biopsy techniques support more precise, individualized treatment plans by providing detailed molecular insights that help guide targeted cancer therapies.

Segmented by biomarker type, the market from cfDNA segment is expected to maintain a strong CAGR of 22.5% in 2023. This popularity is attributed to cfDNA's ability to reveal real-time tumor dynamics, offering early detection and insights into treatment response and disease progression. Compared to traditional tissue biopsies, cfDNA provides a comprehensive genomic profile and can detect emerging mutations linked to drug resistance, increasing its utility in cancer diagnostics.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$305.9 Million
Forecast Value$1.9 Billion
CAGR22.6%

In terms of products and services, the market is divided into kits & reagents and service offerings, with kits & reagents holding a significant 67.1% share in 2023. These components play a pivotal role in the liquid biopsy, thus facilitating non-invasive diagnostic procedures. The rising prevalence of breast cancer has intensified demand for these kits, driving ongoing research and new product launches in early cancer detection.

North America breast cancer liquid biopsy market in 2023, with a valuation of USD 133.3 million. The country's advanced healthcare infrastructure and substantial R&D investments foster the implementation of liquid biopsy technologies as non-invasive substitutes to traditional methods. The escalating incidence of breast cancer in the U.S. has further spurred demand for these innovative diagnostic tools, underscoring the region's leadership in this market.

As a result, the global breast cancer liquid biopsy market is expected to grow significantly, driven by technology innovations, early cancer detection efforts, and a growing emphasis on patient-specific treatment strategies. This expansion reflects the increasing shift toward minimally invasive diagnostic techniques that offer improved accuracy and patient outcomes.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of breast cancer
      • 3.2.1.2 Technological advancements in liquid biopsy technique
      • 3.2.1.3 Rising awareness for early diagnosis and treatment
      • 3.2.1.4 Expansion of research and development
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of biopsy devices
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Epidemiology scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Biomarkers, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Circulating Tumor Cells (CTCs)
  • 5.3 Cell-free DNA (cfDNA)
  • 5.4 Exosomes
  • 5.5 Other biomarkers

Chapter 6 Market Estimates and Forecast, By Product & Services, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Kits & reagents
  • 6.3 Services

Chapter 7 Market Estimates and Forecast, By Sample Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Blood
  • 7.3 Urine
  • 7.4 Other sample types

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Cancer research centers
  • 8.4 Diagnostic centers
  • 8.5 Academic and research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Datar Cancer Genetics
  • 10.2 Epic Sciences
  • 10.3 F. Hoffmann-La Roche
  • 10.4 Genes2me
  • 10.5 Illumina
  • 10.6 Menarini Silicon Biosystems
  • 10.7 Myriad Genetics
  • 10.8 OncoDNA
  • 10.9 QIAGEN
  • 10.10 Sysmex Corporation
  • 10.11 System Biosciences
  • 10.12 Thermo Fisher Scientific
  • 10.13 Twist Bioscience